
About MegaPro Biomedical
MegaPro Biomedical is a publicly listed company based in Hsinchu (Taiwan) founded in 2014. Developer of niche-type nano-drugs for cancer. It operates in the Healthcare and Technology sectors. The company has 27 employees. Its chief executive, as recorded, is Jassy Wang. Its focus areas include Life Sciences, Hematology, Drugs and Diversified.
Company details
MegaPro Biomedical was founded in 2014 in Hsinchu, Taiwan, within the biotechnology sector. Proprietary PEGylated iron oxide nanoparticles, branded as IOP Injection, are developed as a contrast agent for magnetic resonance imaging. Additionally, this non-sugar-based intravenous iron formulation is targeted for iron-deficiency anemia and hepatocellular carcinoma treatments. Operations center on advancing these niche pharmaceutical applications through research and development.
- Headquarters Hsinchu, Taiwan
- Employees 27
- Stage Public
- SectorsHealthcareTechnology
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website megaprobio.com
- Legal Name Megapro Biomedical Co., Ltd.
- Net Profit-$119.1 M27.39as on Dec 31, 2025
- EBITDA-$104.53 M35.86as on Dec 31, 2025
- Employee Count27
People of MegaPro Biomedical
1 people are tracked at MegaPro Biomedical (1 in leadership); the tracked headcount is 27.
| Name | Role | Group |
|---|---|---|
Jassy Wang | CEO | Leadership |
Complete people profiles for MegaPro Biomedical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of MegaPro Biomedical
MegaPro Biomedical is a publicly listed company on the TPEX with ticker symbol 6827 in Taiwan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date19 Oct 2021
- Listed onTT: 6827
- Listed entityMegaPro Biomedical Co., Ltd.
- Exchange sectorHealth technology
- ISINTW0006827009
- Share price13.65 TWD (+0.37% on the day) · 2026-10-14
- Market capitalisation1,069,085,250.00 TWD
- EPS (diluted, trailing year)-1.29 TWD
- Volume (last session)641,441
Financials of MegaPro Biomedical
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -119.1M TWD | -104.5M TWD | |
| 2024 | 14,000 TWD | -164.0M TWD | -163.0M TWD |
| 2023 | 18,000 TWD | -127.5M TWD | -123.9M TWD |
| 2022 | -111.7M TWD | -108.2M TWD | |
| 2021 | -89.2M TWD | -93.4M TWD |
Detailed financial statements for MegaPro Biomedical
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about MegaPro Biomedical
MegaPro Biomedical was founded in 2014.
MegaPro Biomedical is headquartered in Hsinchu, Taiwan.
Jassy Wang is the CEO of MegaPro Biomedical, as recorded in our data.
MegaPro Biomedical has 27 employees.
MegaPro Biomedical was founded in 2014 in Hsinchu, Taiwan, within the biotechnology sector. Proprietary PEGylated iron oxide nanoparticles, branded as IOP Injection, are developed as a contrast agent for magnetic resonance imaging. Additionally, this non-sugar-based intravenous iron formulation is targeted for iron-deficiency anemia and hepatocellular carcinoma treatments. Operations center on advancing these niche pharmaceutical applications through research and development.
Yes, MegaPro Biomedical is publicly traded on TPEX under the ticker symbol 6827.